Compare Ally Financial Inc (ALLY) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ally Financial Inc vs Boston Scientific Corporation — how do they compare? Ally Financial Inc trades at $45.64 (market cap $13.97B), while Boston Scientific Corporation trades at $44.83 (market cap $66.54B). The key difference: Boston Scientific Corporation is far larger — about 4.8× Ally Financial Inc's market cap, and Ally Financial Inc pays a 2.63% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ALLY | BSX | |
|---|---|---|
Market Cap | $13.97B | $66.54B |
Sector | Financials | Health |
52-Week High | $47.25 | $108.14 |
52-Week Low | $35.96 | $42.68 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $76.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
Boston Scientific (BSX) trades at $44.77, down 0.49% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $12.7B in 2022 to $20.1B in 2025, with net income margin expanding to 17.29%. Recent earnings beats and a 88% analyst buy rating contrast with the stock's 60% decline from its 2025 high, creating a significant valuation gap versus the $72.38 consensus target.
BSX presents a compelling value opportunity with attractive valuation metrics (P/E 18.73, P/S 3.25) and strong profitability, though investors face near-term technical weakness and competitive pressures in key segments like electrophysiology. The stock's current price represents a 38% discount to analyst targets, suggesting substantial upside potential for patient investors despite recent market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
